PMID- 33062677
OWN - NLM
STAT- MEDLINE
DCOM- 20210503
LR  - 20220417
IS  - 2314-6141 (Electronic)
IS  - 2314-6133 (Print)
VI  - 2020
DP  - 2020
TI  - Wubeizi Ointment Suppresses Keloid Formation through Modulation of the mTOR 
      Pathway.
PG  - 3608372
LID - 10.1155/2020/3608372 [doi]
LID - 3608372
AB  - BACKGROUND: Wubeizi (Rhus chinensis Mill.) ointment has been shown as an 
      effective treatment for keloids. However, the protective mechanisms of Wubeizi 
      ointment are not fully understood. The mammalian target of rapamycin (mTOR) has 
      been demonstrated to be associated with keloid pathogenesis. In the present 
      study, we investigated if Wubeizi ointment suppressed keloid formation through 
      the modulation of key molecules of the rapamycin (mTOR) pathway including 
      phosphatase and tensin homolog (PTEN), phosphatidylinositol 3-kinase (PI3K), and 
      protein kinase B (Akt). METHODS: A keloid mouse model and human keloid-derived 
      fibroblasts were developed and treated with Galla chinensis. 
      Immunohistochemistry, western blot, and reverse transcription-PCR were used to 
      detect PI3K, PTEN, Akt, and mTOR in keloid tissues and keloid fibroblasts. The 
      apoptosis and proliferation rate of keloid fibroblasts was, respectively, 
      analyzed by flow cytometry according to the MTT assay. Statistical analysis was 
      done using SPSS version 20.0. For two variable comparisons, a two independent 
      samples t-test was used. For multiple variable comparisons, data were analyzed by 
      one-way analysis of variance (ANOVA) followed by pairwise q-tests. RESULTS: Our 
      in vivo and in vitro studies showed that Wubeizi ointment suppressed keloid 
      formation through inhibition of fibroblast proliferation and promotion of 
      fibroblast apoptosis. The underlying basis involves downregulation of p-Akt and 
      p-mTOR as well as upregulation of PTEN. CONCLUSION: These findings may contribute 
      to a better understanding of the mechanisms of Wubeizi ointment for treating 
      keloids.
CI  - Copyright (c) 2020 Zhiming Tang et al.
FAU - Tang, Zhiming
AU  - Tang Z
AUID- ORCID: 0000-0002-3037-1000
AD  - The First Clinical Medical College, Zhejiang Chinese Medical University, 
      Hangzhou, China.
AD  - Department of Dermatology, Xuzhou Hospital Affiliated to Nanjing University of 
      Traditional Chinese Medicine, Xuzhou, China.
FAU - Cao, Yi
AU  - Cao Y
AUID- ORCID: 0000-0003-2471-211X
AD  - Department of Dermatology, The First Affiliated Hospital of Zhejiang Chinese 
      Medical University, Hangzhou, China.
FAU - Ding, Jicun
AU  - Ding J
AUID- ORCID: 0000-0001-7163-8296
AD  - Department of Burns and Plastic Surgery, Xuzhou Central Hospital, Xuzhou, China.
FAU - Zhai, Xiaoxiang
AU  - Zhai X
AUID- ORCID: 0000-0003-1527-1236
AD  - Department of Dermatology, Shanghai Seventh People's Hospital, Shanghai, China.
FAU - Jing, Mengqing
AU  - Jing M
AUID- ORCID: 0000-0001-9431-6396
AD  - Department of Dermatology, Xuzhou Hospital Affiliated to Nanjing University of 
      Traditional Chinese Medicine, Xuzhou, China.
FAU - Wang, Mengmeng
AU  - Wang M
AUID- ORCID: 0000-0001-8699-4496
AD  - Department of Dermatology, Xuzhou Hospital Affiliated to Nanjing University of 
      Traditional Chinese Medicine, Xuzhou, China.
FAU - Lu, Lu
AU  - Lu L
AUID- ORCID: 0000-0002-1231-5494
AD  - Department of Dermatology, Xuzhou Hospital Affiliated to Nanjing University of 
      Traditional Chinese Medicine, Xuzhou, China.
LA  - eng
PT  - Journal Article
DEP - 20200930
PL  - United States
TA  - Biomed Res Int
JT  - BioMed research international
JID - 101600173
RN  - 0 (Drugs, Chinese Herbal)
RN  - 0 (Ointments)
RN  - 0 (wubeizi)
RN  - EC 2.7.1.1 (mTOR protein, mouse)
RN  - EC 2.7.11.1 (Proto-Oncogene Proteins c-akt)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
SB  - IM
MH  - Adult
MH  - Animals
MH  - Apoptosis/drug effects
MH  - Cell Proliferation/drug effects
MH  - Cells, Cultured
MH  - Drugs, Chinese Herbal/*pharmacology
MH  - Female
MH  - Fibroblasts/drug effects
MH  - Humans
MH  - Keloid/*metabolism/pathology
MH  - Male
MH  - Mice
MH  - Mice, Nude
MH  - Ointments
MH  - Proto-Oncogene Proteins c-akt/genetics/*metabolism
MH  - Signal Transduction/*drug effects
MH  - TOR Serine-Threonine Kinases/genetics/*metabolism
MH  - Young Adult
PMC - PMC7545458
COIS- The authors declare that there is no conflict of interest regarding the 
      publication of this paper.
EDAT- 2020/10/17 06:00
MHDA- 2021/05/04 06:00
PMCR- 2020/09/30
CRDT- 2020/10/16 05:56
PHST- 2020/06/12 00:00 [received]
PHST- 2020/08/13 00:00 [revised]
PHST- 2020/09/16 00:00 [accepted]
PHST- 2020/10/16 05:56 [entrez]
PHST- 2020/10/17 06:00 [pubmed]
PHST- 2021/05/04 06:00 [medline]
PHST- 2020/09/30 00:00 [pmc-release]
AID - 10.1155/2020/3608372 [doi]
PST - epublish
SO  - Biomed Res Int. 2020 Sep 30;2020:3608372. doi: 10.1155/2020/3608372. eCollection 
      2020.